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Department of Biological Sciences, University of Warwick, Coventry, United KingdomABSTRACT Prion diseases are neurodegenerative disorders of the central nervous system that are associated with the mis-
folding of the prion protein (PrP). PrP is glycosylphosphatidylinositol-anchored, and therefore the hydrophobic membrane
environment may inﬂuence the process of prion conversion. This study investigates how the morphology and mechanism of
growth of prion aggregates on membranes are inﬂuenced by lipid composition. Atomic force microscopy is used to image the
aggregation of prions on supported lipid bilayers composed of mixtures of the zwitterionic lipid, 1-palmitoyl-2-oleoyl-sn-glyc-
ero-3-phosphocholine (POPC) and the anionic lipid, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoserine (POPS). Circular
dichroism shows that PrP interactions with POPS membranes result in an increase in b-sheet structure, whereas interactions
with POPC do not inﬂuence PrP structure. Prion aggregation is observed on both zwitterionic and anionic membranes, and
the morphology of the aggregates formed is dependent on the anionic phospholipid content of the membrane. The aggregates
that form on POPC membranes have uniform dimensions and do not disrupt the lipid bilayer. The presence of POPS results in
larger aggregates with a distinctive sponge-like morphology that are disruptive to membranes. These data provide detailed
information on the aggregation mechanism of PrP on membranes, which can be described by classic models of growth.INTRODUCTIONPrion diseases are a group of fatal neurodegenerative disor-
ders that include Creutzfeldt-Jakob disease (CJD) in humans,
bovine spongiform encephalopathy (BSE) in cattle, and
scrapie in sheep. Such diseases can manifest as infectious,
sporadic, or familial, and are all associated with the misfold-
ing of the normal cellular form of the prion protein, PrPC,
into the disease-associated isoform, PrPSc (1). This misfold-
ing event involves the conformational rearrangement of
PrPC from a soluble, protease-sensitive form that is rich in
a-helical structure to an aggregated form, PrPSc, that is rich
in b-sheet structure (2) and is proteinase K-resistant (3).
Aggregated deposits of the misfolded PrP are found in the
brain on autopsy and are accompanied by vacuolation, astro-
cytosis, and neuronal loss (4). The aggregates that form are
morphologically diverse and include ordered amyloid fibers
and amorphous material (5,6). Although the mechanisms of
toxicity are unknown, it is established that PrPC expression
is required in the host for neuronal cell death (7) and disease
development (8), which indicates that the aggregation of
host-encoded PrP results in cell death. However, since detect-
able levels of PrPSc are not always associated with disease
(9,10), smaller oligomeric species that are more difficult to
detect may be the toxic PrP species.
Understanding the biochemical processes of prionmisfold-
ing and aggregation will help us to understand the initiation
and progression of prion disease. Therefore, various studies
have attempted to mimic the structural transition and asso-
ciated fibrillization of PrP in vitro (11–14). Such studies
have highlighted the multiple pathways of protein misfoldingSubmitted August 26, 2009, and accepted for publication December 2, 2009.
*Correspondence: t.pinheiro@warwick.ac.uk
Editor: Peter Hinterdorfer.
 2010 by the Biophysical Society
0006-3495/10/04/1520/9 $2.00and the formation of structurally distinct misfolded PrP
isoforms. The majority of studies have focused on fibrilliza-
tion of PrP in solution; however, since PrP is glycosylphos-
phatidylinositol (GPI)-anchored, it is closely associated with
lipid membranes (15), and therefore it is important to study
the influence of the lipid membrane environment on the
aggregation of PrP.
Folding studies of PrP in solution have indicated that
the a-helical and b-sheet-rich isoforms of PrP are separated
by an energy barrier involved in the unfolding and subse-
quent oligomerization of PrP (16). Our hypothesis is that the
hydrophobic membrane environment may lower this energy
barrier to promote prion conversion. This hypothesis is sup-
ported by the fact that acidic phospholipids have been shown
to promote protein misfolding and amyloid formation for a
number of amyloidogenic and nonamyloidogenic proteins
(17). This property has been attributed to 1), the hydrophobic
nature of the lipid membrane core, which promotes pro-
tein unfolding; 2), the surface properties of membranes that
enable them to effectively concentrate protein, which
promotes protein-protein interactions; and 3), the ability of
acidic membranes to neutralize positively charged clusters
on the surface of proteins, which prevents repulsion between
protein molecules and promotes oligomerization.
We previously showed that recombinant, truncated
PrP binds to model membranes composed of palmitoylo-
leoylphosphatidyglycerol (1-palmitoyl-2-oleoyl-sn-glycero-
3-phosphoglycerol) (POPG). This binding event results in
a structural rearrangement of PrP to a conformation that is
rich in b-sheet and prone to aggregation (18). In the study
presented here, we used 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC), a zwitterionic phospholipid, anddoi: 10.1016/j.bpj.2009.12.4304
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glycero-3-phosphoserine) (POPS), an anionic phospholipid.
These phospholipids are highly representative of the two
major phospholipids in neuronal cell membranes (19).
Under native conditions, phosphatidylserines are exclusively
located on the cytoplasmic side of the membrane and there-
fore should not come into contact with PrP. However, under
pathological conditions, exposure of POPS to the outer leaflet
of the membrane could result in an abnormal interaction with
PrP. In this study, we used atomic force microscopy (AFM)
to image the assembly of prion aggregates on POPC and
mixtures of POPC/POPS supported lipid bilayers (SLBs).
SLBs consist of a lipid bilayer deposited on a solid support.
The membrane is separated from the support by a nano-
meter-thick layer of water, which enables diffusion of lipid
molecules within the plain of the membrane such that the
bilayer retains the lateral fluidity of an unsupported free
bilayer (20).
For this study, the truncated prion domain PrP(90-231),
refolded to the native a-helical conformation of PrPC, was
used. The sequence of this fragment corresponds to the
proteinase K-resistant fragment of PrPSc that is associated
with the infectious core of PrP. Therefore, the use of this
protein domain is highly pertinent and biologically relevant.
Because PrP(90-231) lacks the GPI anchor, the observed
interactions result from the affinity of the polypeptide chain
for the membrane. The use of AFM enabled us to follow
in situ the aggregation events of PrP on SLBs. This technique
was previously used to image the aggregation of amyloido-
genic proteins, such as Ab filaments (21), prion fragments
(22), and islet amyloid polypeptide (23).
The morphology of prion aggregates observed by AFM on
SLBs is correlated to protein structure changes in vesicle
systems. The results show that PrP aggregation is directed
down distinct pathways by the types of lipid present in the
membrane, and we propose growth models to describe this
aggregation process.MATERIALS AND METHODS
Details of the expression and purification of PrP and vesicle preparations are
provided in the Supporting Material.Binding assay
The binding of PrP to POPC lipid vesicles was assayed by sucrose gradient
centrifugation. PrP in 5 mMMES, pH 5, was mixed with vesicles to obtain a
lipid/protein molar ratio of 400, and the sample was then incubated for>1 h.
This sample was adjusted to 40% (w/v) sucrose to obtain a total volume of
800 mL, which was then overlaid with a 30% sucrose layer (3 mL) followed
by a 5% sucrose layer (1 mL) to form a discontinuous sucrose gradient.
The samples were centrifuged at 140,000 g in a Beckman SW50.1 rotor at
4C for 16 h. Fractions (0.5 mL) spanning the entire gradient were taken
from the top and analyzed by Western dot blotting to detect protein. For
this purpose, 150 mL of each fraction were taken, and the protein was
precipitated with acetone and then resuspended in 30 mL of resuspension
buffer (62.5 mM Tris-HCL, pH 6.8, 2% SDS). Then 3  10 mL aliquotsof the resuspended protein were spotted onto a Hybond-ECL nitrocellulose
membrane (Amersham Biosciences, Bucks, UK) and immunostrained
using mAb1562 IgG (Chemicon International, Watford, UK) at 1:8000
dilution followed by alkaline phosphatase conjugated anti-mouse IgG at
1:5000 dilution. The immunostained protein was visualized using 2 mL
of Western blue stabilized substrate for alkaline phosphatase (Promega,
Southampton, UK).Light scattering
Lipid-containing fractions from the sucrose density gradient were identified
by light scattering on a Photon Technology International (Ford, UK) spec-
trofluorometer, using a 4 mm pathlength quartz cuvette. Synchronous scans
(200–300 nm) were recorded with excitation light (1 nm bandwidth) and
emission light (0.5 nm bandwidth) set to the same wavelengths. Spectra
were collected with a step size of 1 nm and an integration time of 0.5 s,
and values were taken at 280 nm as a measure of light scattering.Circular dichroism
For each measurement, a concentrated stock of vesicles was titrated into
a 250 mL aliquot of 8 mM PrP. Far-UV (190–260 nm) circular dichroism
(CD) spectra were measured on a JASCO J-815 spectropolarimeter using a
1 mm path length quartz cuvette. Typically, a scanning rate of 100 nm /min,
a time constant of 1 s, and a bandwidth of 1.0 nm were used. Spectra were
measured at 20C with a resolution of 0.5 nm, and typically eight or 16 scans
were averaged per spectrum. The corresponding appropriate backgrounds
(buffer for protein solutions, or lipid alone at corresponding concentrations
for lipid-protein samples) were subtracted from the final spectra.Preparation of SLBs and AFM
AFM measurements were performed with a Nanoscope V atomic force
microscope (Veeco, Santa Barbara, CA) equipped with a J scanner (120 mm)
and a tapping-mode fluid cell. The measurements were obtained using
triangular silicon nitride cantilevers (spring constant ~0.12 N/m) with
oxide-sharpened tips (Veeco). Mica, mounted on a BYTAC-coated metal
support disk, was freshly cleaved and installed on the scanner. The fluid
cell containing the cantilever and an S-shaped silicon O-ring was assembled
on top. The fluid cell, O-ring, and tubing were cleaned with 2% SDS
solution and rinsed with copious amounts of nanopure water before each
experiment.
SLBs were prepared directly in the fluid cell of the atomic force micro-
scope by exposing the freshly cleaved mica to the vesicle solution at a lipid
concentration of 0.5 mg/mL in 10 mM HEPES, pH 7.4, containing 2 mM
CaCl2 and 150 mM NaCl. After an incubation period of 30–40 min, excess
vesicles and salt were removed by exchanging the buffer with 10 mM
HEPES, pH 7.4. The bilayer was then equilibrated with 5 mM MES,
pH 5, and imaged to ensure that the bilayer was intact. Freshly thawed
PrP(90-231) in 5 mM MES, pH 5, was injected over the bilayer at concen-
trations between 0.3 and 2 mM. Exposure to air was carefully avoided at all
times.RESULTS
PrP binds to POPC vesicles and retains its native
structure
We previously reported fluorescence and CD data indicating
that PrP does not bind to POPC membranes (18). However,
a recent study detected an interaction by separating a mixture
of PrP and POPC vesicles on a sucrose density gradient (24),
and data obtained by dual-polarization interferometry showBiophysical Journal 98(8) 1520–1528
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fore apparent that fluorescence and CD measurements may
not be able to detect low levels of binding, due to the large
proportion of free protein that dominates the spectrum. To
confirm that PrP binds to POPC membranes, we performed
a sucrose gradient binding assay (Fig. 1). PrP alone localizes
to the bottom of the gradient (fractions 9 and 10), but on
incubation with POPC vesicles, PrP becomes distributed
across the higher fractions (1–5), with free protein remaining
in fractions 8–10. The location of PrP in fractions 1–5 corre-
lates with the presence of the lipid vesicles as detected by
light scattering (Fig. 1 B). Estimates from an ultracentrifuga-
tion binding assay suggest that ~30% of PrP binds to the lipid
vesicles (data not shown).
The far-UV CD spectrum of PrP contains two defined
minima at 208 and 222 nm that are characteristic of a-helical
structure. On incubation with POPC vesicles, the spectra
retains its shape (Fig. 2A), which shows that there is no detect-
able change in the secondary structure of PrP on binding to
POPC vesicles.FIGURE 1 Sucrose density separation of PrP bound to POPC lipid vesi-
cles. (A) Western dot blot analysis of fractions taken from a sucrose density
gradient containing (i) PrP alone and (ii) PrP incubated with POPC lipid
vesicles. Numbers 1–10 indicate the fractions from the top to the bottom
of the gradient (C is the PrP-positive control). (B) Light-scattering measure-
ments of corresponding fractions indicating the location of lipid vesicles.
Error bars represent the standard error of three independent light-scattering
measurements.
FIGURE 2 Secondary structure of PrP in solution and on incubation with
POPC and POPS. Far-UV CD spectra of PrP in solution (solid line) and on
incubation with (A) POPC at lipid/protein ratios of 100 (dotted line) and 500
(dashed line), and (B) in the presence of POPS (dash-dot line) at a lipid/
protein ratio of 3.75.
Biophysical Journal 98(8) 1520–1528PrP binds to POPS lipid membranes and results
in an increase in b-sheet structure
In contrast to POPC, the presence of POPS results in a
dramatic change in the shape of the CD spectrum (Fig. 2 B).
The spectrum becomes more rounded, showing a single
minimum around 220 nm, disappearance of signal at 208 nm,
and attenuation of the band around 190–195 nm. The shape of
this spectrum represents a protein that is rich in b-sheet struc-
ture. The band at ~216 nm, which is typical of b-sheet struc-
ture in solution, red-shifts to ~220 nm because the b-sheet
structure is present in a lipid membrane environment.
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membranes (26), including PrP (18).
PrP forms ﬂat clusters on POPC membranes
The growth of prion aggregates on POPC SLBs was charac-
terized by AFM. After the first injection of PrP onto the
POPC SLB, small protein clusters could be visualized on
the surface (Fig. 3 A). After further injections of protein,
these nuclei grew across the surface of the membrane to
form larger round, flat structures (Fig. 3, B–D). The growth
of clusters is clearly illustrated in Fig. 3, B0 and C0, where the
same clusters at different stages of growth can be visualized
between panels. The aggregates grow until they fuse with
each other (Fig. 3 D) and the protein layer begins to saturate
the lipid membrane.
A section analysis reveals that the aggregates grow to a
stable height of 5 nm (Fig. 3, B00–D00), which is equivalent
to ~1 molecule of PrP, judging by the NMR structure (27).
Once they have reached this height, they do not grow verti-
cally in height despite further injections of PrP. The section
analysis also shows that the aggregates form and spread
across the surface without penetrating and disrupting the
bilayer. This is highlighted in the section analysis by the
maintenance of a horizontal bilayer that surrounds the clus-
ters (Fig. 3, A00–D00).
Within each condition, the size of the aggregates on the
POPC SLB appear uniform in size (Fig. 3), which indicates
an ordered mechanism of growth. Therefore, a size distribu-
tion of the particles was calculated for each data set (Fig. 4).
After the first injection of PrP, nuclei form with a mean
diameter of 94 nm, and after the next two injections theWidth (µm)
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The diameters of the clusters correspond to ~18, 39, and
61 molecules of PrP. The clusters grow in a protein concen-
tration-dependent manner (Fig. 4, inset) until they fuse with
neighboring aggregates.
PrP forms holey, sponge-like aggregates
on POPC/POPS membranes
SLBs prepared on mica from vesicles containing anionic
lipids show an asymmetric distribution of anionic lipids
between bilayer leaflets (28), with the amount of POPS
exposed to solution lower than the lipid composition of the
vesicles. A previous study showed that for vesicles containing
50%, 40%, and 20% POPS, only 20%, 15%, and 7% POPS,
respectively, is exposed in the outer leaflet of SLB (28).
SLBs were formed from vesicles containing 20% POPS,
resulting in an upper lipid leaflet containing ~7% POPS.
On injection of PrP, aggregates form that are similar in
morphology to those grown on POPC alone (Fig. 5).
A comparison of the clusters shown in Fig. 5, A and B, with
those in Fig. 3, C and D, reveals that they are very similar in
appearance. Section analysis reveals that these aggregates
have the same height (5 nm) as those grown on POPC alone
(Fig. 5, A0 and B0). Again these clusters grow across the
membrane as more protein is added, and do not disrupt the
bilayer. Fig. 5 C shows the presence of larger and thicker
protein aggregates that form between existing clusters. These
domains are ~10 nm in height and could therefore represent
a second layer of protein. As these aggregates are not
observed in the POPC lipid system, they are likely to result
from the presence of POPS in the membrane. Section5
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FIGURE 3 Growth of prion aggre-
gates on POPC SLBs. Each panel shows
a POPC SLB with successive 0.5 mL
additions of 0.5 mM PrP (A–C) and
(D) 2 mM PrP. The image size (Z-scale)
of panels A–D is 8  8 mm (30 nm).
A0–D0 are zoomed-in versions of panels
A–D as indicated by the dashed boxes.
The image size (Z-scale) of panels
A0–D0 is 2.5 mm  2.5 mm (25 nm).
Cross-section analysis (A00–D00) reveals
the height profiles across the surface
along the corresponding white lines in
panels A–D.
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FIGURE 4 Size distribution of prion clusters formed on POPC SLBs.
Each data set shows the size distribution of 350 particles selected from the
corresponding images that make up Fig. 3, A–C. The size distribution of
the particles is shown after successive additions of 0.5 mL of 0.5 mM PrP
(white), a further 0.5 mM PrP (black), and a further 0.5 mM PrP (gray). Inset
shows the mean size of the aggregates plotted against the amount of protein
added, with error bars representing the standard deviation.
1524 Robinson and Pinheiroanalysis of the aggregates over the membrane reveals minor
membrane disruptions (Fig. 5 C0).
We further increased the concentration of POPS in the
mixed membrane system to see how it would affect prion
aggregation. SLBs were formed from vesicles of 40% POPS
(Fig. 6), resulting in an upper lipid leaflet containing ~15%
POPS. The aggregates formed in this bilayer system wereH
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Biophysical Journal 98(8) 1520–1528strikingly different from those grown on POPC alone.
Fig. 6 A shows the formation of protein aggregates that
contain holes, which makes them sponge-like in appearance.
The same area of panel A is imaged in panels B and C, and
therefore the growth of the aggregates can be observed as
more protein is injected and the sample is incubated. Distinct
nucleation sites are visible in panel A, which can be identified
in panelsB andC. On addition of protein, these grow outward,
away from the nucleation sites and across the surface of the
membrane. On further incubation (Fig. 6 C), the aggregates
grow further and saturate the membrane.
Section analysis reveals the formation of pores that pene-
trate into themembrane (Fig. 6A000). Therefore, in the presence
of POPS, PrP aggregation clearly disrupts the lipidmembrane,
in contrast to the aggregation of PrP on POPC bilayers.DISCUSSION
PrP is a GPI-anchored protein and therefore is localized to the
outer leaflet of the plasma membrane (29). This close associ-
ation with lipid membranes indicates that prion conversion
is likely to occur in a membrane environment. We previously
showed that PrP(90-231) interacts with membranes contain-
ing the anionic phospholipid POPG, promoting an increase
in b-sheet structure (18) and amorphous aggregation (30).
In this study, we investigated how phospholipid content
affects the growth and morphology of prion aggregates on
membranes composed of the zwitterionic phospholipid
POPC and the anionic phospholipid POPS.
PrP binds peripherally to POPC membranes
Previous data obtained by fluorescence, CD, and attenuated
total reflection Fourier transform infrared (ATR-FTIR) indi-
cated that PrP does not interact with POPC lipid vesicles
(18,30,31). In contrast, Re et al. (24) recently detectedWidth (µm)
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FIGURE 5 Growth of prion aggre-
gates on POPS/POPC bilayers (~7%
POPS). Each panel shows a POPS/
POPC SLB (~7% POPS in the outer
leaflet) with successive additions of
0.5 mL of 0.5 mM PrP (A and B), and
(C) incubation after the previous addi-
tion of protein. The image size (Z-scale)
of panels A and B is 8  8 mm (75 nm),
and the insets are 1.5 1.5 mm (25 nm).
The image size (Z-scale) of panel C is
25  25 mm (75 nm). Cross-section
analysis (A0–C0) reveals the height pro-
files taken at areas indicated by white
lines in the corresponding panels.
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FIGURE 6 Growth of PrP aggregates
on POPC/POPS bilayers (~15% POPS).
Each panel shows an SLB with the
addition of (A) 0.5 mL of 1 mM PrP,
(B) a further 0.5 mL of 1 mM PrP, and
(C) incubation for 1 h after the second
injection of protein. The image size
(Z-scale) of panels A–C is 25  25 mm
(70 nm). Panels A0 and A00 are zoomed-
in versions of panel A as indicated by
dashed lines. The image size (Z-scale)
of A0 is 10  10 mm (30 nm) and the
image size (Z-scale) of A00 is 4  4 mm
(30 nm). Cross-section analysis reveals
the height profiles taken at areas indi-
cated by black and white lines.
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a sucrose density gradient. To confirm whether PrP(90-231)
binds to POPC lipid membranes, we employed a sucrose
gradient centrifugation binding assay (Fig. 1), which clearly
showed evidence of binding. The interaction between PrP
and POPC is therefore detectable by separation techniques,
but not by spectroscopic techniques that rely on significant
protein structure changes or insertion into the membrane.
As a result, the interaction with POPC does not induce
a detectable change in PrP structure, and thus there is no
change in the CD spectrum (Fig. 2). Overall, the fact that
PrP binds to POPC lipid membranes with no significant
penetration into the membrane or change in protein structure
indicates that the interaction is peripheral.
Further evidence for the peripheral interaction between
PrP and POPC comes from the formation of PrP clusters
on POPC SLBs, as observed by AFM. These clusters grow
laterally across the membrane in a consistently ordered
fashion that is dependent on protein concentration. The
height of the clusters (~5 nm) is consistent with the thickness
of layers of full-length PrP on POPC SLBs (4.65 0.7 nm),
as measured by dual-polarization interferometry (25). In
addition, previous studies have shown that the small hydro-
phobic peptide PrP(106-126) forms similar structures on
the surface of POPC SLBs (22). It is difficult to compare
those structures with the ones presented here, because the
former were obtained with a much shorter PrP fragment.
However, they appear to form aggregates that are dense
and clustered in appearance. A noticeable difference is that
PrP(106-126) forms pores in the POPC membrane, whereas
the PrP(90-231) aggregates are clearly not disruptive to the
membrane. The ability of this peptide to disrupt membranes
in contrast to the complete globular domain of PrP may berelated to the neurotoxic properties of the PrP(106-126)
fragment (32).
In vivo POPC is present on the exoplasmic face of the
plasma membrane, which is the same leaflet where all
GPI-anchored proteins, including PrP, are located. Since
GPI anchors do not extend across the whole bilayer, GPI-
anchored proteins are not bound as strongly to membranes
as transmembrane proteins (33). It is therefore possible that
the protein-lipid interactions between PrP and POPC con-
tribute to the association of PrP with lipid membranes and
help retain the association of PrP with the bilayer. PrP forms
ordered aggregates on POPC SLBs but does not disrupt the
membrane. This is consistent with previous fluorescence dye
release assays (18) that showed that PrP does not disrupt
POPC lipid vesicles. This evidence suggests that an interac-
tion between POPC and PrP is unlikely to initiate cell death
via membrane destabilization in vivo, and therefore these
clusters are unlikely to be toxic.PrP aggregation on membranes containing POPS
In the presence of 7% POPS, aggregates formed on the SLB
have a morphology similar to that of aggregates grown on
POPC alone. Therefore, at this level of POPS, the greater
content of POPC drives the aggregation process, even though
PrP binds with higher affinity to POPS (31). Only on incuba-
tion do we see the formation of larger aggregates that are
distinctly different in morphology from those formed on
POPC. This suggests that the majority of protein on the
membrane aggregates via the same pathway observed on
the POPC bilayer, and only the smaller amounts of protein
bound to POPS initiate an alternative aggregation pathway
that results in the formation of the larger aggregates over time.Biophysical Journal 98(8) 1520–1528
1526 Robinson and PinheiroWhen the POPS concentration is increased to ~15%, local-
ized protein aggregates form with a sponge-like appearance
as a result of membrane-disrupting pores that are visible as
holes within the aggregates (Fig. 6). These aggregates are
distinctly different in morphology from those formed on
POPC bilayers (Fig. 3), and therefore the increased concen-
tration of POPS, which gives the membrane surface a nega-
tive charge, significantly alters the PrP aggregation pathway.
Binding to POPS results in increased b-sheet structure, and
such b-sheet aggregates induce membrane disruption, as
previously shown (30). Therefore, the alternative pathway
is likely to result from the altered protein structure and
disruption to the membrane. The fact that the aggregates
formed on the 15% POPS membrane are distinctly different
from those grown on 7% POPS indicates that a threshold
level of POPS has to be reached for the charge density to
be high enough to influence prion aggregation. This observa-
tion correlates with studies claiming that clustered negative
charges are required on the membrane surface for b-sheet
formation (34) and PrP-induced membrane disruption (35).
In addition to lipids, a variety of other negatively charged
molecules have been shown to influence prion conversion,
including glycosaminoglycans (36–38), DNA (39), and
RNA (40,41). A large amount of evidence therefore suggests
that anionic molecules may be crucial cofactors for prion
conversion. Furthermore, in a previous study (42), infectious
prions were formed in the absence of exogenous PrPSc
through protein misfolding cyclic amplification (PMCA)
by the addition of polyanionic molecules to native PrPC.
This reaction contained lipid molecules that copurified
with the protein, which led to the conclusion that the minimal
components required to form infectious prions are PrPC,
lipids, and anionic molecules. This finding, combined with
the fact that anionic phospholipids clearly induce the mis-
folding of PrP and influence its aggregation pathway,
suggests that anionic phospholipids may be cofactors for
the prion conversion process.PrP aggregation on POPS membranes induces
membrane disruption
A variety of amyloidogenic proteins have been shown to
form pore-like structures in lipid bilayers (43), and this is
a possible mechanism of cell death in prion disease.We previ-
ously showed that membrane disruption occurs on interaction
between PrP and anionic lipid membranes (18), and that
membrane permeability is an early event in PrP-induced
neurotoxicity (44). On SLBs with low POPS content (i.e.,
7% POPS (Fig. 5)), there is no evidence formembrane disrup-
tion, which correlates with the fact that the morphology of the
aggregates is similar to that observed on POPC alone. When
POPS content is increased to 15%, the distinctly different PrP
aggregates induce membrane disruption.
Disruption is likely to be induced by PrP through interac-
tions with the hydrophobic core of the membrane. This isBiophysical Journal 98(8) 1520–1528supported by studies conducted in transgenic mice and
cultured cells, which showed that cytosolic PrP (cyPrP)
interacts with the hydrophobic core of the lipid membrane
in cells from the cerebellum, correlating with the location
of neuronal loss (45). Therefore, there is a strong link
between PrP interactions with the hydrophobic core of the
membrane and neurotoxicity.
Because interactions between PrP and POPS clearly
result in protein misfolding and membrane disruption, this
interaction in vivo is likely to lead to cell death. POPS
flip-flops through diffusion in both directions across the
membrane, but the action of amino phospholipid flipase
enzymes, which make internal transport more efficient,
result in an asymmetrical POPS distribution (46,47). As
a result, POPS is located exclusively on the cytoplasmic
side of the membrane, and thus under normal circumstances
PrP and POPS should be located on different sides of the
membrane. However, a number of physiologically relevant
events have been documented that can result in membrane
scrambling and the presence of POPS on the exoplasmic
side of the membrane. These include cellular activation,
the presence of amphiphilic drugs, and the effects of
anesthetics (46,47). A loss of POPS symmetry also occurs
during apoptosis (48), which is then a signal for macro-
phages to engulf the cell. Therefore, in normal, healthy
cells, PrP and POPS should be efficiently separated, pre-
venting a pathological PrP-POPS interaction. However,
the loss of POPS asymmetry in vivo is likely to result in
a PrP-POPS interaction, which would result in protein mis-
folding and membrane disruption, leading to a spontaneous
prion disease.Aggregation mechanisms of PrP on SLBs
It is apparent that the shape of any growth form depends on
themechanism bywhich it originates. Therefore, it is possible
to deduce a mechanism of aggregation from the structure of
the aggregates formed. When we compare the morphology
of the aggregates that form on POPC (Fig. 3) and POPC/
POPS (Fig. 6) systems, it is clear that they grow through
different mechanisms. In an attempt to describe these mecha-
nisms of aggregation, we researched models that have been
used to describe the growth of natural phenomena. The
Eden model was originally used to describe the growth of
bacterial cells on a substrate (49), and the growth of PrP aggre-
gates on POPCmembranes seems to fit this model. If so, then
a site on the membrane is randomly occupied by the PrP
molecule (Fig. 7), and the nearest neighbors to this point
(i.e., the surrounding membrane) become potential sites for
the next molecule of PrP to bind. At the next time point,
one of the potential sites is randomly occupied by another
PrP molecule, and again the nearest neighbors of the newly
occupied site become potential growth sites. This process is
repeated until a large cluster of occupied sites is formed
and the PrP aggregate can be visualized on the surface of
A B
FIGURE 7 Proposed mechanisms of growth of PrP aggregates on lipid
membranes. (A) Diagram illustrating the Eden model of growth, with gray
circles representing bound PrP and white circles representing potential
growth sites. (B) Diagram following the epidemic model of growth, with
gray circles representing bound PrP, white circles representing potential
growth sites, and black circles representing sites of membrane disruption,
where growth cannot occur.
Prion Aggregation Pathways 1527the membrane. This process continues until the PrP aggre-
gates fuse with their nearest neighbors.
In 7% POPS membranes, no disruption of the bilayer is
observed and the aggregates are similar to those formed on
POPCmembranes (Fig. 5, A and B). These aggregates appear
to grow according to the Eden model of growth. This
suggests that the dominating factor driving the aggregation
process in this lipid system is the interaction between PrP
and POPC. On incubation, larger aggregates are detectable,
which shows that POPS is influencing the growth of a
subpopulation of aggregates, resulting in a mixture of aggre-
gates. When the content of POPS in the SLBs is increased
(Fig. 6), the growth of the aggregates fits the epidemic model
of growth (Fig. 7). In this model, sites on the membrane are
randomly occupied by PrP; then, the nearest neighbors
either become potential sites of occupancy or are killed so
that they can never be occupied. In membranes where 15%
POPS is present, PrP is converted to b-sheet structure, dis-
rupting the lipid membrane and resulting in a site that can
no longer become occupied. However, the other sites adja-
cent to the PrP aggregate where the membrane is still intact
are still potential sites of growth. The aggregates therefore
grow around holes in the membrane, resulting in the forma-
tion of large networks of sponge-like aggregates across the
membrane.
Overall, the data presented in this study provide new
insights into how lipid membranes can induce prion aggrega-tion, and how the constituents of the membrane can direct
prions down alternative aggregation pathways. Zwitterionic
lipid preserves the a-helical structure of PrP and promotes
a continuous mode of aggregate growth. Negatively charged
lipid induces b-sheet structure, which disrupts the membrane
and results in holey aggregates. To our knowledge, this is
the first time that such aggregates have been imaged at the
level of detail shown here, revealing two distinct mecha-
nisms of growth that are dependent on the lipid content of
the membrane.SUPPORTING MATERIAL
Additional methods are available at http://www.biophysj.org/biophysj/
supplemental/S0006-3495(10)00005-6.
We acknowledge the CIC biomaGUNE (San Sebastia´n, Spain) for providing
AFM facilities and expertise. We also thank Robin Ball, University of War-
wick (Coventry, UK), for discussions on growth models of aggregates.
This project was funded by the Biotechnology and Biological Sciences
Research Council (grant BB/D524516/1) and a studentship (88/DTA19176)
to P.J.R.REFERENCES
1. Prusiner, S. B. 1998. Prions. Proc. Natl. Acad. Sci. USA. 95:
13363–13383.
2. Caughey, B. W., A. Dong,., W. S. Caughey. 1991. Secondary struc-
ture analysis of the scrapie-associated protein PrP 27-30 in water by
infrared spectroscopy. Biochemistry. 30:7672–7680.
3. Oesch, B., D. Westaway, ., C. Weissmann. 1985. A cellular gene
encodes scrapie PrP 27-30 protein. Cell. 40:735–746.
4. Bell, J. E., and J. W. Ironside. 1993. Neuropathology of spongiform
encephalopathies in humans. Br. Med. Bull. 49:738–777.
5. Giaccone, G., L. Verga,., F. Tagliavini. 1992. Prion protein preamy-
loid and amyloid deposits in Gerstmann-Stra¨ussler-Scheinker disease,
Indiana kindred. Proc. Natl. Acad. Sci. USA. 89:9349–9353.
6. Jeffrey, M., I. A. Goodbrand, and C. M. Goodsir. 1995. Pathology of the
transmissible spongiform encephalopathies with special emphasis on
ultrastructure. Micron. 26:277–298.
7. Brandner, S., S. Isenmann, ., A. Aguzzi. 1996. Normal host prion
protein necessary for scrapie-induced neurotoxicity. Nature. 379:
339–343.
8. Bu¨eler, H., A. Aguzzi,., C. Weissmann. 1993. Mice devoid of PrP are
resistant to scrapie. Cell. 73:1339–1347.
9. Collinge, J., M. S. Palmer, ., P. Lantos. 1995. Transmission of fatal
familial insomnia to laboratory animals. Lancet. 346:569–570.
10. Lasme´zas, C. I., J. P. Deslys, ., D. Dormont. 1997. Transmission of
the BSE agent to mice in the absence of detectable abnormal prion
protein. Science. 275:402–405.
11. Swietnicki, W., M. Morillas, ., W. K. Surewicz. 2000. Aggregation
and fibrillization of the recombinant human prion protein huPrP90-
231. Biochemistry. 39:424–431.
12. Baskakov, I. V., G. Legname, ., F. E. Cohen. 2002. Pathway
complexity of prion protein assembly into amyloid. J. Biol. Chem.
277:21140–21148.
13. Bocharova, O. V., L. Breydo,., I. V. Baskakov. 2005. In vitro conver-
sion of full-length mammalian prion protein produces amyloid form
with physical properties of PrP(Sc). J. Mol. Biol. 346:645–659.
14. Baskakov, I. V., and O. V. Bocharova. 2005. In vitro conversion of
mammalian prion protein into amyloid fibrils displays unusual features.
Biochemistry. 44:2339–2348.Biophysical Journal 98(8) 1520–1528
1528 Robinson and Pinheiro15. Stahl, N., D. R. Borchelt,., S. B. Prusiner. 1987. Scrapie prion protein
contains a phosphatidylinositol glycolipid. Cell. 51:229–240.
16. Baskakov, I. V., G. Legname,., F. E. Cohen. 2001. Folding of prion
protein to its native a-helical conformation is under kinetic control.
J. Biol. Chem. 276:19687–19690.
17. Zhao, H., E. K. Tuominen, and P. K. Kinnunen. 2004. Formation of
amyloid fibers triggered by phosphatidylserine-containing membranes.
Biochemistry. 43:10302–10307.
18. Sanghera, N., and T. J. Pinheiro. 2002. Binding of prion protein to
lipid membranes and implications for prion conversion. J. Mol. Biol.
315:1241–1256.
19. van Meer, G. 1989. Lipid traffic in animal cells. Annu. Rev. Cell Biol.
5:247–275.
20. Sackmann, E. 1996. Supported membranes: scientific and practical
applications. Science. 271:43–48.
21. Zhang, L., J. Zhong,., Y. Sha. 2008. Parallel-oriented fibrogenesis of
a b-sheet forming peptide on supported lipid bilayers. J. Phys. Chem. B.
112:8950–8954.
22. Zhong, J., W. Zheng, ., Y. Sha. 2007. PrP106-126 amide causes the
semi-penetrated poration in the supported lipid bilayers. Biochim. Bio-
phys. Acta. 1768:1420–1429.
23. Domanov, Y. A., and P. K. Kinnunen. 2008. Islet amyloid polypeptide
forms rigid lipid-protein amyloid fibrils on supported phospholipid bila-
yers. J. Mol. Biol. 376:42–54.
24. Re, F., S. Sesana, ., M. Masserini. 2008. Prion protein structure is
affected by pH-dependent interaction with membranes: a study in
a model system. FEBS Lett. 582:215–220.
25. Sanghera, N., M. J. Swann,., T. J. Pinheiro. 2009. Insight into early
events in the aggregation of the prion protein on lipid membranes.
Biochim. Biophys. Acta. 1788:2245–2251.
26. Knight, J. D., J. A. Hebda, and A. D. Miranker. 2006. Conserved and
cooperative assembly of membrane-bound a-helical states of islet
amyloid polypeptide. Biochemistry. 45:9496–9508.
27. James, T. L., H. Liu, ., F. E. Cohen. 1997. Solution structure of
a 142-residue recombinant prion protein corresponding to the infectious
fragment of the scrapie isoform. Proc. Natl. Acad. Sci. USA. 94:
10086–10091.
28. Richter, R. P., R. Be´rat, and A. R. Brisson. 2006. Formation of solid-
supported lipid bilayers: an integrated view. Langmuir. 22:3497–3505.
29. Caughey, B., and G. J. Raymond. 1991. The scrapie-associated form of
PrP is made from a cell surface precursor that is both protease- and
phospholipase-sensitive. J. Biol. Chem. 266:18217–18223.
30. Kazlauskaite, J., N. Sanghera, ., T. J. Pinheiro. 2003. Structural
changes of the prion protein in lipid membranes leading to aggregation
and fibrillization. Biochemistry. 42:3295–3304.
31. Morillas, M., W. Swietnicki, ., W. K. Surewicz. 1999. Membrane
environment alters the conformational structure of the recombinant
human prion protein. J. Biol. Chem. 274:36859–36865.
32. Forloni, G., N. Angeretti, ., F. Tagliavini. 1993. Neurotoxicity of
a prion protein fragment. Nature. 362:543–546.Biophysical Journal 98(8) 1520–152833. Paulick, M. G., and C. R. Bertozzi. 2008. The glycosylphosphatidylino-
sitol anchor: a complex membrane-anchoring structure for proteins.
Biochemistry. 47:6991–7000.
34. Miura, T., M. Yoda,., H. Takeuchi. 2007. Clustered negative charges
on the lipid membrane surface induce b-sheet formation of prion protein
fragment 106-126. Biochemistry. 46:11589–11597.
35. Henriques, S. T., L. K. Pattenden,., M. A. Castanho. 2008. PrP(106-
126) does not interact with membranes under physiological conditions.
Biophys. J. 95:1877–1889.
36. Shaked, G. M., Z. Meiner, ., R. Gabizon. 2001. Reconstitution of
prion infectivity from solubilized protease-resistant PrP and nonprotein
components of prion rods. J. Biol. Chem. 276:14324–14328.
37. Ben-Zaken, O., S. Tzaban, ., A. Taraboulos. 2003. Cellular heparan
sulfate participates in the metabolism of prions. J. Biol. Chem. 278:
40041–40049.
38. Caughey, B., and R. E. Race. 1994. Scrapie-associated PrP accumula-
tion and its inhibition: revisiting the amyloid-glycosaminoglycan
connection. Ann. N. Y. Acad. Sci. 724:290–295.
39. Nandi, P. K., E. Leclerc,., M. Takahashi. 2002. DNA-induced partial
unfolding of prion protein leads to its polymerisation to amyloid. J. Mol.
Biol. 322:153–161.
40. Deleault, N. R., R. W. Lucassen, and S. Supattapone. 2003. RNA mole-
cules stimulate prion protein conversion. Nature. 425:717–720.
41. Adler, V., B. Zeiler, ., A. Grossman. 2003. Small, highly structured
RNAs participate in the conversion of human recombinant PrP(Sen) to
PrP(Res) in vitro. J. Mol. Biol. 332:47–57.
42. Deleault, N. R., B. T. Harris, ., S. Supattapone. 2007. Formation of
native prions from minimal components in vitro. Proc. Natl. Acad.
Sci. USA. 104:9741–9746.
43. Quist, A., I. Doudevski, ., R. Lal. 2005. Amyloid ion channels:
a common structural link for protein-misfolding disease. Proc. Natl.
Acad. Sci. USA. 102:10427–10432.
44. Sanghera, N., M. Wall, ., T. J. Pinheiro. 2008. Globular and pre-
fibrillar prion aggregates are toxic to neuronal cells and perturb their
electrophysiology. Biochim. Biophys. Acta. 1784:873–881.
45. Wang, X., F. Wang, ., J. Ma. 2006. The interaction between cyto-
plasmic prion protein and the hydrophobic lipid core of membrane
correlates with neurotoxicity. J. Biol. Chem. 281:13559–13565.
46. Boon, J. M., and B. D. Smith. 2002. Chemical control of phospholipid
distribution across bilayer membranes. Med. Res. Rev. 22:251–281.
47. Zachowski, A. 1993. Phospholipids in animal eukaryotic membranes:
transverse asymmetry and movement. Biochem. J. 294:1–14.
48. Martin, S. J., C. P. Reutelingsperger,., D. R. Green. 1995. Early redis-
tribution of plasma membrane phosphatidylserine is a general feature of
apoptosis regardless of the initiating stimulus: inhibition by overexpres-
sion of Bcl-2 and Abl. J. Exp. Med. 182:1545–1556.
49. Eden, M. 1960. A two-dimensional growth process. Proc. Berkeley
Symp. Math. Stat. Prob., 4th, Berkeley. 223–239.
